BioTuesdays
Athira Pharma
Markets

BTIG starts Athira Pharma at buy; PT $33

BTIG launched coverage of Athira Pharma (NASDAQ:ATHA) with a “buy” rating and $33 price target. The stock closed at $8.84 on May 9. Athira is developing fosgonimeton for the treatment of Alzheimer’s disease, pervasive...

May 10, 2022
Markets

Maxim starts Oncternal at buy; PT $3.50

Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...

May 10, 2022
180-Life-Sciences
Markets

Maxim cuts 180 Life Sciences to hold; withdraws PT

Maxim Group downgraded 180 Life Sciences (NASDAQ:ATNF) to “hold” from “buy” and withdrew its price target, citing a financing overhang. The stock closed at $1.31 on May 6. Several weeks ago, 180 announced the...

May 9, 2022
Amarin
Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022
Aligos-Therapeutics
Markets

SVB cuts Aligos to market perform; PT to $3 from $7

SVB Securities downgraded Aligos Therapeutics (NASDAQ:ALGS) to “market perform” from “outperform” and slashed its price target to $3, which is close to cash, from $7, citing a slow catalyst path ahead with a legal...

May 5, 2022
Shattuck Labs
Markets

HCW starts Shattuck Labs at buy; PT $28

H.C. Wainwright initiated coverage of Shattuck Labs (NASDAQ:STTK) with a “buy” rating and price target of $28. The stock closed at $3.84 on April 29. To overcome the shortcomings of current immunomodulatory cancer...

May 2, 2022
Vera-Therapeutics
Markets

HCW starts Vera Therapeutics at buy; PT $35

H.C. Wainwright launched coverage of Vera Therapeutics (NASDAQ:VERA) with a “buy” rating and $35 price target. The stock closed at $20 on April 29. Vera is a clinical-stage biotech company focused on developing disease...

May 2, 2022
acutus logo
Markets

BTIG ups Acutus Medical to buy; PT $2

BTIG upgraded Acutus Medical (NASDAQ:AFIB) to “buy” from “neutral” with a price target of $2, after the company announced a debt refinancing and the sale of its left-heart access product portfolio that should extend its...

April 27, 2022
Opthea-Logo
Markets

SVB starts Opthea at OP; PT $25

SVB Securities launched coverage of Opthea (NASDAQ:OPT) with an “outperform” rating and $25 price target. The stock closed at $5.71 on April 25. Opthea is a clinical-stage biotechnology company focused on developing...

April 26, 2022
Markets

Maxim starts Processa Pharma at buy; PT $9

Maxim Group initiated coverage of Processa Pharmaceuticals (NASDAQ:PCSA) with a “buy” rating and $9 price target. The stock closed at $2.87 on April 18. Processa is a clinical-stage company developing therapies for...

April 19, 2022
AN2 Theraputics
Markets

SVB Leerink starts AN2 Therapeutics at OP; PT $27

SVB Leerink launched coverage of AN2 Therapeutics (NASDAQ:ANTX) with an “outperform” rating and price target of $27. The stock closed at $14.79 on April 18.   AN2 is a clinical-stage biotech company developing therapies...

April 19, 2022
Biodesix Logo
Markets

BTIG ups Biodesix PT to $17 from $10

BTIG raised its price target for Biodesix (NASDAQ:BDSX) to $17 from $10, saying “performance this year should restore investor confidence.” The stock closed at $1.61 on April 14. Analyst Sung Ji Nam writes that the...

April 15, 2022
Graphite Bio
Markets

BTIG starts Graphite Bio at buy; PT $18

BTIG initiated coverage of Graphite Bio (NASDAQ:GRPH) with a “buy” rating and price target of $18. The stock closed at $4.15 on April 13. “We believe Graphite Bio’s homology directed repair technology platform...

April 14, 2022
Alpha Tau
Markets

Cantor starts Alpha Tau Medical at OW; PT $20

Cantor Fitzgerald launched coverage of Alpha Tau Medical (NASADQ:DRTS) with an “overweight” rating and $20 price target. The stock closed at $10.58 on April 13. Alpha Tau, which went public in March 2022, is a medical...

April 14, 2022
Synaptogenix
Markets

Maxim starts Synaptogenix at buy; PT $14

Maxim Group launched coverage of Synaptogenix (NASDAQ:SNPX) with a “buy” rating and price target of $14. The stock closed at $7.03 on April 11. Synaptogenix, formerly Neurotrope, is continuing development of bryostatin...

April 12, 2022
Syndax Pharma Logo
Markets

HCW starts Syndax Pharma at buy; PT $31

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and $31 price target. The stock closed at $17.51 on April 8. Syndax is a clinical-stage biopharmaceutical company focused on...

April 11, 2022
Dyadic
Markets

Dawson James halves Dyadic PT to $3

Dawson James halved its price target for Dyadic International (NASDAQ:DYAI) to $3 from $6, citing the company’s C1 platform and whether it will be adopted by a major vaccine maker anytime soon. The stock closed at $2.48...

April 8, 2022
Agile Therapeutics
Markets

Maxim cuts Agile Therapeutics to hold; removes PT

Maxim Group downgraded Agile Therapeutics (NASDAQ:AGRX) to “hold” from “buy” and removed its price target, citing a financing overhang. The stock closed at 16 cents on April 7. Analyst Naz Rahman writes that Agile ended...

April 8, 2022
Gracell Biotechnologies
Markets

BTIG starts Gracell at buy; PT $18 

BTIG initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with a “buy” rating and $18 price target, “with upside potential driven by value inflection points in the next 12-to-24 months.” The stock closed at $2.33...

April 4, 2022